

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTec CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2020 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) for financial year 2020 (the “**2020 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 29, 2020

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*

I. Important Notice

- 1.1 The board of directors (the “**Board**”), the supervisory committee and the directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2020 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2020 Third Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 All directors of the Company attended the Board meeting to review the 2020 Third Quarterly Report.
- 1.3 Ge Li, the person in charge of the Company, Ellis Bih-Hsin Chu, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2020 Third Quarterly Report.
- 1.4 The 2020 Third Quarterly Report of the Company has not been audited.
- 1.5 Definitions

Definitions of frequently-used terms

“2019 Profit Distribution Plan”	the profit distribution plan of the Company for the year ended December 31, 2019 including the Capitalization of Reserve and the distribution of cash dividend of RMB3.37 for every 10 Shares (inclusive of tax)
“2018 A Share Incentive Plan”	Restricted A Shares and Stock Option Incentive Plan of 2018 of the Company
“2019 A Share Incentive Plan”	Restricted A Share and Stock Option Incentive Plan of 2019 of the Company
“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Award”	an award granted by the Board to a Selected Participant, which may vest in the form of award shares or the actual selling price of the award shares in cash, as the Board may determine in accordance with the terms of the rules of the H Share Award and Trust Scheme
“BLA”	biologics license application

“CDMO”	Contract Development and Manufacturing Organization, a CMO that in addition to comprehensive drug manufacturing services, also provides process development and other drug development services in connection with its manufacturing services
“CDS”	Clinical Development Services
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, excludes Hong Kong, Macau and Taiwan
“CMO”	Contract Manufacturing Organization, a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive drug manufacturing services
“Company”, “the Company” or “WuXi AppTec”	WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司)
“COVID-19”	Corona Virus Disease 2019
“CRO”	Contract Research Organization
“CSRC”	China Securities Regulatory Commission
“Director(s)”	the director(s) of the Company
“end of the Reporting Period”	September 30, 2020
“FDA”	U.S. Food and Drug Administration
“Group”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“H Share Award and Trust Scheme”	the H Share award and trust scheme proposed to be adopted by the Company in accordance with the rules of the H Share Award and Trust Scheme

“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“Incentive Participants”	the persons to be granted Restricted A Share(s), Share Option(s) under the 2018 A Share Incentive Plan and the 2019 A Share Incentive Plan, including the Directors, senior management, mid-level management, backbone members of technicians, basic-level management and other technicians of the Company
“Placing Agreement”	the conditional placing agreement dated July 29, 2020 entered into between the Company and the placing agents in relation to the Placing
“Reporting Period”	the period from January 1, 2020 to September 30, 2020
“Restricted A Shares” or “Restricted Shares”	the restricted A Shares granted by the Company under the 2018 A Share Incentive Plan and 2019 A Share Incentive Plan
“RMB” or “RMB million”	Renminbi yuan or million yuan
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“Shareholder(s)”	holder(s) of Shares
“Share Options”	share options granted under the 2018 A Share Incentive Plan and/or the 2019 A Share Incentive Plan
“SMO”	Site Management Organization
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction

* For identification purpose only

II. Company Profile

The Company is a leading global pharmaceutical research and development services platform. Headquartered in Shanghai, China, the Company provides comprehensive and integrated platform services of discovery, development and manufacturing of small molecule drugs for over 4,100 customers (active customers) through 29 operation sites and branch offices across the globe, including in China, U.S. and Europe. It provides global pharmaceutical companies with discovery, manufacturing and supporting services of new drugs through a platform covering the entire industry chain, and also offers certain testing services for medical devices as well as research, development and manufacturing services of precision medicine. As at the end of the Reporting Period, the Company had 25,743 employees, including 8,387 employees with a master's or higher degree and 1,105 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

Position	China (including Hong Kong)	U.S.	Europe	Total
Research and development	20,408	945	54	21,407
Manufacturing	1,774	233	0	2,007
Sales	24	80	11	115
Management and administration	1,781	428	5	2,214
Total	<u>23,987</u>	<u>1,686</u>	<u>70</u>	<u>25,743</u>

To maintain the high service standards, industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote and retain talented individuals.

2.1 Major financial data

			Unit: RMB
	As at the end of the Reporting Period	As at the end of the previous year	Increase/ decrease of the end of the Reporting Period as compared to the end of the previous year (%)
Total assets	44,514,742,469.14	29,239,134,370.82	52.24
Net assets attributable to shareholders of the Company	31,896,267,121.03	17,312,255,409.07	84.24
	From the beginning of the year to the end of the Reporting Period (January to September)	From the beginning of the previous year to the end of last reporting period (January to September)	Year-on-year increase/ decrease (%)
Net cash flow from operating activities	2,421,904,868.13	1,773,185,018.60	36.59
	From the beginning of the year to the end of the Reporting Period (January to September)	From the beginning of the previous year to the end of last reporting period (January to September)	Year-on-year increase/ decrease (%)
Revenue	11,814,802,985.22	9,278,514,251.38	27.34
Net profit attributable to shareholders of the Company	2,368,356,528.79	1,765,146,773.87	34.17
Net profit attributable to shareholders of the Company after deducting non-recurring gain or loss items	1,653,896,640.54	1,714,238,075.88	-3.52
Weighted average return on equity (%)	11.89	9.89	increased by 2.00 percentage points
Basic earnings per share (RMB/share)	1.03	0.77	33.77
Diluted earnings per share (RMB/share)	1.02	0.76	34.21

1. Total assets and net assets attributable to shareholders of the Company

Total assets and net assets attributable to shareholders of the Company increased by 52.24% and 84.24%, respectively, as compared with the end of 2019, mainly due to the increase in the balance of assets and equity as a result of the completion of the placing of H Shares and non-public issuance of A Shares during the Reporting Period.

2. Net cash flow from operating activities

Net cash flow from operating activities of the Company for the period increased by 36.59% to RMB2,421.9049 million, as compared with the corresponding period of the previous year, mainly due to the growth of the principal business of the Company, timely collection and effective cost and payment control of the Company.

3. Revenue

In the third quarter of 2020, our revenue grew by 35.44% year-over-year (YoY) to RMB4,583.3690 million due primarily to:

- (1) Our China-based laboratory services realized revenue of RMB2,337.6317 million, representing a YoY growth of 38.88%. Both of our small molecule drug discovery services and laboratory testing services achieved strong growth. Revenue from fee for services grew by approximately 53% YoY while revenue from our drug safety assessment services grew by approximately 77% YoY.
- (2) Our CDMO/CMO services realized revenue of RMB1,548.1117 million, representing a YoY growth of 54.91%. For the first three quarters in 2020, in pursuit of our “follow-the-molecule” development strategy, we added over 440 new molecules into our small molecule CDMO/CMO services pipeline, including 25 phase II/III clinical trial projects we won from external sources (including our clients and their current CMOs). As of September 30, 2020, our small molecule CDMO/CMO pipeline has grown to more than 1,100 active projects, including 42 projects in Phase III clinical trials and 26 in commercial manufacturing.

- (3) Our U.S.-based laboratory services realized revenue of RMB372.3849 million, representing a YoY decline of 13.45%, mainly due to the impact of COVID-19 and customer project delays. As of September 30, 2020, our U.S. cell and gene therapies CDMO business provided services for 33 clinical stage projects, including 22 projects in Phase I and 11 projects in Phase II/III. We expect at least 2 projects will file for BLA with the FDA in 2021, which may become a key growth driver for our U.S.-based laboratory services.
- (4) Despite the impact of COVID-19, clinical research and other CRO services realized revenue of RMB314.6335 million, representing a YoY growth of 16.78%. The revenue growth rate continued to improve quarter-over-quarter. The backlog of our clinical research and other CRO services increased significantly compared with the same period last year. The backlog of our CDS services increased about 100% and the backlog of our SMO services increased about 45%.

In the first three quarters of 2020, our revenue grew by 27.34% YoY to RMB11,814.8030 million due primarily to: (1) our China-based laboratory services realized revenue of RMB6,117.5896 million, representing a YoY growth of 30.94%; (2) our CDMO/CMO services realized revenue of RMB3,709.6142 million, representing a YoY growth of 36.53%; (3) our U.S.-based laboratory services realized revenue of RMB1,154.0419 million, representing a YoY growth of 1.22%; and (4) our clinical research and other CRO services realized revenue of RMB814.6311 million, representing a YoY growth of 9.86%.

4. *Net profit attributable to shareholders of the Company*

Net profit attributable to shareholders of the Company for the Reporting Period recorded an increase of 34.17% as compared with the corresponding period of the previous year. While the main business of the Company has grown significantly, the gains and change in fair value of investment for the Reporting Period were RMB411.2392 million and RMB312.0907 million, respectively, representing a total increase of RMB655.9127 million as compared to the corresponding period of the previous year. The significant increase was mainly due to the increase in the market value of the investees, resulting in the increase of fair value changes and gains in investment.

5. *Weighted average return on equity*

Weighted average return on equity increased by 2.00 percentage points, mainly due to the increase in net profit attributable to shareholders of the Company for the Reporting Period resulting from higher operating income and fair value changes and gains in investment as compared to the corresponding period of the previous year. In addition, the weighted average owners' equity for the Reporting Period increased due to the completion of the placing of H Shares and non-public issuance of A Shares.

6. *Earnings per share*

The basic earnings per share and diluted earnings per share increased by 33.77% and 34.21%, respectively, as compared with the corresponding period of the previous year, mainly due to the significant growth of net profit attributable to shareholders of the Company for the Reporting Period.

In June 2020, pursuant to the 2019 Profit Distribution Plan considered and approved at the shareholders' general meeting held on May 15, 2020, the Company issued 4 Shares for every 10 Shares of the Company by way of capitalization of reserve and 660,450,612 Shares were issued in aggregate. The total share capital of the Company increased from 1,651,126,531 Shares to 2,311,577,143 Shares. The Company has calculated the basic and diluted earnings per share for the Reporting Period and adjusted the earnings per share for the comparative period according to the increased number of shares issued. On the other hand, the outstanding weighted average number of shares for the period also slightly increased by the completion of the placing of H Shares and non-public issuance of A Shares in August and September 2020, respectively.

Non-recurring gain or loss items and amounts

Applicable

Not applicable

Unit: RMB

Item	Amount for the period (July to September)	Amount for the period from the beginning of the year to the end of the Reporting Period (January to September)	Description
Gain or loss on disposal of non-current assets	-2,299,157.68	-5,283,781.46	
Government grants included in profit or loss of the current period (except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations)	32,801,831.71	127,672,281.22	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other equity investments, except effective hedging business related to the Company's normal operations	145,576,726.11	672,588,438.67	From January to September 2020, mainly include: a gain of RMB771.1033 million from fair value changes in investment, an investment gain of RMB351.4908 million as a result of the change of accounting method for our investment in shares of associates, a gain of RMB132.8956 million from disposal of investment, investment income and gain on disposal of held-for-trading financial assets of RMB58.9614 million, a gain of RMB65.7370 million from fair value changes in and settlement of foreign currency forward contracts, offset by a loss of RMB676.4149 million from fair value changes in convertible bonds and fair value changes in financial liabilities of RMB31.1847 million.
Other non-operating income and expenses other than the above items	-6,434,900.98	-15,579,484.68	
Impact on minority interests (after tax)	-2,130,764.48	-2,464,141.20	
Effect of income tax	-39,100,300.42	-62,473,424.30	
Total	<u>128,413,434.26</u>	<u>714,459,888.25</u>	

2.2 Total number of Shareholders and shareholdings of top 10 Shareholders and top 10 holders of tradable Shares (or Shareholders holding Shares not subject to trading restrictions) as at the end of the Reporting Period

Unit: share
97,040

Full name of Shareholder	Shareholdings of top 10 Shareholders					
	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to trading restrictions	Pledged or frozen Shares Status	Number	Nature of Shareholders
HKSCC NOMINEES LIMITED (Note 1)	306,892,706	12.5672	0	Nil	0	Overseas legal entity
G&C VI Limited	158,760,000	6.5012	158,760,000	Nil	0	Overseas legal entity
Hong Kong Securities Clearing Company Limited	153,919,807	6.3030	0	Unknown	0	Overseas legal entity
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	145,124,379	5.9428	0	Nil	0	Overseas legal entity
G&C IV Hong Kong Limited	116,099,424	4.7542	116,099,424	Nil	0	Overseas legal entity
WuXi AppTec (BVI) Inc.	94,140,725	3.8550	0	Nil	0	Overseas legal entity
G&C V Limited	81,124,596	3.3220	81,124,596	Nil	0	Overseas legal entity
Shanghai Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership)	72,562,140	2.9714	72,562,140	Nil	0	Domestic non-state owned legal entity
Glorious Moonlight Limited	58,003,498	2.3752	0	Nil	0	Overseas legal entity
G&C VII Limited	42,012,600	1.7204	42,012,600	Nil	0	Overseas legal entity

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Name of Shareholder	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED (Note 1)	306,892,706	Overseas-listed foreign shares	306,892,706
Hong Kong Securities Clearing Company Limited	153,919,807	RMB-denominated ordinary shares	153,919,807
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	145,124,379	RMB-denominated ordinary shares	145,124,379
WuXi AppTec (BVI) Inc.	94,140,725	RMB-denominated ordinary shares	94,140,725
Glorious Moonlight Limited	58,003,498	RMB-denominated ordinary shares	58,003,498
Hillhouse Capital Management, Ltd. -HCM Fund II (QFII)	25,356,686	RMB-denominated ordinary shares	25,356,686
CDB Boyu (Shanghai) Investment Management Company Limited — Jiashi Kangheng (Tianjin) Investments Partnership (Limited Partnership)	24,720,814	RMB-denominated ordinary shares	24,720,814
UBS AG	19,105,258	RMB-denominated ordinary shares	19,105,258
The Hongkong and Shanghai Banking Corporation Limited	18,875,075	RMB-denominated ordinary shares	18,875,075
Bank of China Limited — CMF Bio-pharmaceutical Index Securities Investment Fund (招商國證生物醫藥指數分級 證券投資基金)	14,223,983	RMB-denominated ordinary shares	14,223,983
Description of connected relationships or concerted actions of the above Shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited and G&C VII Limited, being part of the top 10 shareholders of the Company, are under the control of Ge Li. Close family member(s) of Xiaomeng Tong (a director of the Company who was nominated by Glorious Moonlight Limited, being part of the top 10 holders of Shares not subject to trading restrictions of the Company) holds shares of Boyu (Shanghai) Investment Management Company Limited, the ultimate controller of Jiashi Kangheng (Tianjin) Investments Partnership (Limited Partnership).		
Description of preference shareholders with voting rights restored and their shareholdings	Not applicable		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

2.3 Total number of preference Shareholders and shareholdings of top 10 preference Shareholders and top 10 preference Shareholders not subject to trading restrictions as at the end of the Reporting Period

Applicable Not applicable

III. Significant Events

3.1 Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

Applicable Not applicable

Unit: RMB

Item of Consolidated Income Statement	From the beginning of the year to the end of the Reporting Period (January – September)	From the beginning of last year to the end of the reporting period of last year (January – September)	Change (%)	Reasons
Revenue	11,814,802,985.22	9,278,514,251.38	27.34	It was mainly due to the faster growth of orders from overseas customers, higher capacity utilization and operating efficiency, and significant growth of China-based laboratory services and CDMO services.
Cost	7,374,781,534.27	5,612,735,942.99	31.39	During the Reporting Period, cost increase aligned with the revenue trend. The Company continued to strengthen its production capacities and capabilities, and expanded incentives for its key personnel, resulting in a higher increase in cost compared to revenue.
Selling and marketing expenses	410,788,005.00	313,174,962.20	31.17	It was mainly due to the increase in expense incurred for share incentive scheme for sales personnel during the Reporting Period.

Item of Consolidated Income Statement	From the beginning of the year to the end of the Reporting Period (January – September)	From the beginning of last year to the end of the reporting period of last year (January – September)	Change (%)	Reasons
Finance expenses	326,603,223.36	-100,488,321.63	N/A	It was mainly due to the increase in foreign exchange loss resulting from significant appreciation of RMB against USD, increase in interest expenses due to higher average borrowings, and increase in amortization of interest expenses on convertible bonds and rental liabilities during the Reporting Period.
Investment gains	411,239,174.22	199,593,997.90	106.04	It was mainly due to the increase in investment gain of approximately RMB351.4908 million as a result of the change of accounting method for our investment in shares of associates (as announced by the Company on June 11, 2020; please refer to the announcement number: Lin 2020-040), offset by operating losses of certain associates and joint ventures during the Reporting Period.
Gains from changes in fair value	312,090,742.03	-132,176,799.62	N/A	It was mainly due to the increase in fair value of the equity interest in certain listed companies in line with the increase of share prices and the increase in value of non-listed companies during the Reporting Period.
Assets impairment losses	-10,173,426.54	-1,025,136.30	N/A	It was mainly due to higher impairment losses of obsolete long-aging raw materials.
Gains on assets disposal	-4,566,306.12	1,035,391.87	-541.02	It was mainly due to the losses on disposal of fixed assets during the Reporting Period.
Non-operating expenses	18,675,386.55	6,759,572.67	176.28	It was mainly due to the losses on disposal of biological assets during the Reporting Period.

Item of Consolidated Balance Sheet	Closing balance	Opening balance	Year-on-year change (%)	Reasons
Bank balances and cash	13,475,354,163.79	5,227,242,858.56	157.79	During the Reporting Period, the Company completed the placing of H Shares and non-public issuance of A Shares and received a total proceeds of RMB13,030.2538 million.
Financial assets held for trading	3,022,027,021.27	1,701,637,915.47	77.60	It was mainly due to the increase in the purchase of wealth management products during the Reporting Period.
Derivative financial assets	261,067,732.82	36,755,179.22	610.29	It was mainly due to the change in fair value of derivative financial instruments.
Note receivables	3,564,016.00	24,734,692.87	-85.59	It was mainly due to the redemption of note receivables upon expiry.
Prepayments	170,830,093.70	92,158,061.18	85.37	It was mainly due to the increases in deposits for procurement of materials and other prepayments during the Reporting Period.
Other receivables	52,931,424.76	30,891,335.36	71.35	It was mainly due to the increase in tax refund during the Reporting Period.
Inventories	2,362,079,955.55	1,742,485,452.79	35.56	It was mainly due to the growth of CDMO services, higher capacity increased orders from customers which led to increase of inventory reserve.
Contract assets	509,975,788.00	379,395,934.04	34.42	It was mainly due to the growth in business and revenue.
Other non-current financial assets	5,812,706,851.88	4,009,081,069.57	44.99	It was mainly due to additional equity investment in companies of drug research and development and increase in fair value of investees during the Reporting Period.
Other non-current assets	562,724,528.66	50,334,411.99	1,017.97	It was mainly due to the increased investments in the certificates of deposit during the Reporting Period.

Item of Consolidated Balance Sheet	Closing balance	Opening balance	Year-on-year change (%)	Reasons
Derivative financial liabilities	43,680,541.42	86,378,137.81	-49.43	It was mainly due to the change in fair value of derivative financial instruments and the settlement of derivative financial instruments during the Reporting Period.
Note payables	11,818,925.60	19,089,888.52	-38.09	It was mainly due to the settlement of note payables upon expiry.
Trade payables	823,931,431.52	573,097,931.92	43.77	Trade payables increased in line with the increase in inventories during the Reporting Period.
Contract liabilities	1,281,163,042.04	897,139,905.65	42.81	It was mainly due to the growth of all business segments resulting in higher advance payment received upon project commencement.
Non-current liabilities due within one year	186,913,439.36	348,097,143.48	-46.30	It was mainly due to the repayment of the current portion of long-term borrowings during the Reporting Period.
Long-term borrowings	—	762,400,000.00	-100.00	It was mainly due to the repayment of all long-term borrowings during the Reporting Period.
Other non-current liabilities	1,159,074,595.42	554,554,757.31	109.01	It was mainly due to the increase in fair value of derivative component of convertible bonds due to higher stock price of the Company.

Item of Consolidated Cash Flow Statement	From the beginning of the year to the end of the Reporting Period (January – September)	From the beginning of last year to the end of the reporting period of last year (January – September)	Change (%)	Reasons
Net cash flow generated from operating activities	2,421,904,868.13	1,773,185,018.60	36.59	It was mainly due to the growth of main business, timely collection of receivables and effective cost and payment control during the period.
Net cash flow generated from investment activities	-4,566,410,413.85	-3,899,946,133.25	N/A	It was mainly due to the increase in net outflow of cash payment for wealth management products after offsetting the receipt of cash from disposal of equity investment as compared with the corresponding period of the previous year.
Net cash flow generated from financing activities	10,244,054,008.50	1,003,167,883.97	921.17	It was mainly due to the higher cash inflow of proceeds from the placing of H Shares and non-public issuance of A Shares than the cash inflow from the issue of overseas zero coupon convertible bonds during the corresponding period of the previous year.

3.2 Analysis and explanations of the progress of significant events and their impacts and solutions

Applicable Not applicable

1. Completion of the placing

According to the approval of the CSRC in the Reply on Approving the Issuance of Overseas Listed Foreign Capital Shares by WuXi AppTec Co., Ltd. (Zheng Jian Xu Ke [2020] No.1576), the Company issued 68,205,400 H Shares. All the conditions of the Placing Agreement have been satisfied and the completion of the placing took place on August 5, 2020. For details, please refer to the Announcement regarding the Completion of the Issuance and Placing of the New H Shares of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司關於公司完成新增發行H股配售的公告》) (announcement no.: Lin 2020-066) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on August 6, 2020.

2. Cancellation and repurchase of the Restricted A Shares

On June 10, 2020, the Company convened the second meeting of the second session of the Board which considered and approved the Proposal on the Adjustments to the Repurchase Price and Number of Repurchased Shares of Part of the Restricted Shares Granted under the Initial Grant and the Reserved Grant and the Exercise Price and Number of Part of the Share Options Granted under the Reserved Grant of the 2018 A Share Incentive Plan of the Company (《關於調整公司2018年A股股權激勵計劃首次及預留授予部分限制性股票回購價格、數量及預留授予部分期權行權價格、數量的議案》) and the relevant proposals, pursuant to which the Company was approved to repurchase and cancel the Restricted Shares granted but not yet unlocked from a total of 105 Incentive Participants. The adjusted number of repurchased shares was 897,964 A Shares in aggregate. Cancellation of the above repurchased 897,964 A Shares was completed on August 19, 2020. For details, please refer to the Announcement regarding the Repurchase and Cancellation of the Restricted Shares under the Incentive Plans of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司關於股權激勵限制性股票回購註銷實施公告》) (announcement no.: Lin 2020-072) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on August 17, 2020.

3. *H Share Award and Trust Scheme*

On August 31, 2020, the Company convened the first extraordinary general meeting of 2020 which considered and approved the H Share Award and Trust Scheme. In accordance with the H Share Award and Trust Scheme, the Company would provide Computershare Hong Kong Trustees Limited (the “Trustee”) with no more than HK\$700 million to finance the purchase of H Shares from the open market based on the H Share Award and Trust Scheme as a source of the Awards under the H Share Award and Trust Scheme. The purchase was financed with the internal funds of the Company. The final number of H Shares involved in the H Share Award and Trust Scheme will be subject to the actual purchase of H Shares by the Trustee. As such, the specific number is yet to be determined. For details, please refer to the H Share Award and Trust Scheme (Draft) of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司H股獎勵信託計劃(草案)》) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on July 22, 2020.

4. *Results of the reserved grant of the Restricted Shares and the Share Options of the 2019 A Share Incentive Plan*

On June 10, 2020, the Company convened the second meeting of the second session of the Board and the second meeting of the second session of the supervisory committee, both of which considered and approved the Proposal on the Grant of Reserved Interests to the Incentive Participants (《關於向激勵對象授予預留權益的議案》), pursuant to which the Company was approved to grant 427,000 Restricted Shares to 18 Incentive Participants at the price of RMB40.59/share and to grant 29,131 Share Options to one Incentive Participant at the exercise price of RMB81.17/share in accordance with the proposal on June 10, 2020, i.e. the date of the reserved grant. The reserved grant of 383,240 Restricted Shares was registered with the Shanghai Branch of China Securities Depository and Clearing Corporation Limited on September 17, 2020. The relevant registration procedures of the reserved grant of 29,131 Share Options were completed at the Shanghai Branch of China Securities Depository and Clearing Corporation Limited on September 21, 2020. For details, please refer to the Announcement regarding the Results of the Reserved Grant of the Restricted Shares of the 2019 A Share Incentive Plan of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司關於2019年A股股權激勵計劃限制性股票預留授予結果的公告》) (announcement no.: Lin 2020-078) and the Announcement regarding the Results of the Reserved Grant of the Share Options of the 2019 A Share Incentive Plan of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司關於2019年A股股權激勵計劃股票期權預留授予結果的公告》) (announcement no.: Lin 2020-080) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on September 18, 2020 and September 22, 2020, respectively.

5. *Results of partial exercise of the Share Options granted under the reserved grant of the 2018 A Share Incentive Plan during the first exercisable period and the issuance of shares*

On July 21, 2020, the Company convened the third meeting of the second session of the Board and the third meeting of the second session of the supervisory committee, both of which considered and approved the Proposal on the Fulfillment of the Exercise Conditions for the First Exercisable Period of the Share Options Granted under the Reserved Grant of the 2018 A Share Incentive Plan (《關於2018年A股股權激勵計劃預留授予部分股票期權第一個行權期行權條件成就的議案》), pursuant to which the exercise of 160,720 Share Options granted under the reserved grant of the 2018 A Share Incentive Plan by two Incentive Participants during the first exercisable period in accordance with the relevant requirements was approved. According to the Capital Verification Report of De Shi Bao (Yan) Zi (20) No. 00460 issued by Deloitte Touche Tohmatsu (a special general partnership) (德勤華永會計師事務所(特殊普通合夥)), as of August 24, 2020, the Company received RMB2,906,444.80 in cash from one Incentive Participant for the subscription of 62,720 A Shares upon fulfilment of the exercise conditions of the Share Options. Such 62,720 shares were listed on September 23, 2020. For details, please refer to the Announcement regarding the Results of the Partial Exercise of the Share Options Granted under the Reserved Grant of the 2018 A Share Incentive Plan during the First Exercisable Period and the Issuance of Shares of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司關於2018年A股股權激勵計劃預留股票期權第一個行權期部分行權結果暨股份上市公告》) (announcement no.: Lin 2020-077) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on September 18, 2020.

6. *Non-public Issuance of A Shares*

According to the approval of the CSRC in the Reply on Approving the Non-public Issuance of Shares by WuXi AppTec Co., Ltd. (Zheng Jian Xu Ke [2020] No.1828), the Company issued 62,690,290 A Shares (the “**Non-public Issuance of A Shares**”) at the issue price of RMB104.13/share with the total proceed amounting to RMB6,527.9399 million and the net proceed amounting to RMB6,461.2463 million, net of issuance expenses (after tax). The share registration procedures of the Non-public Issuance of A Shares were completed at the Shanghai Branch of China Securities Depository and Clearing Corporation Limited on September 23, 2020. For details, please refer to the Announcement regarding the Results of the Non-public Issuance of Shares and the Change of Share Capital of WuXi AppTec Co., Ltd. (《無錫藥明康德新藥開發股份有限公司非公開發行股票發行結果暨股本變動公告》) (announcement no.: Lin 2020-081) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) and relevant designated media by the Company on September 25, 2020.

3.3 Undertakings not performed during the Reporting Period

Applicable Not applicable

3.4 Caution and explanation as to the anticipated loss of accumulated net profit from the beginning of the year to the end of the next reporting period or significant changes over the same period of last year

Applicable Not applicable

Name of Company	WuXi AppTec Co., Ltd.*
Legal Representative	Ge Li
Date	October 29, 2020

IV. Appendix

4.1 Financial Statement

Consolidated Balance Sheet

As at September 30, 2020

Prepared by: WuXi AppTec Co., Ltd.

Item	Unit: RMB	Type of audit: Unaudited
	As at September 30, 2020	As at December 31, 2019
Current Assets:		
Bank balances and cash	13,475,354,163.79	5,227,242,858.56
Financial assets held for trading	3,022,027,021.27	1,701,637,915.47
Derivative financial assets	261,067,732.82	36,755,179.22
Note receivables	3,564,016.00	24,734,692.87
Trade receivables	3,609,498,992.56	2,936,543,068.55
Prepayments	170,830,093.70	92,158,061.18
Other receivables	52,931,424.76	30,891,335.36
Including: Interest receivables	2,337,823.29	5,229,133.59
Dividend receivables	—	—
Inventories	2,362,079,955.55	1,742,485,452.79
Contract assets	509,975,788.00	379,395,934.04
Other current assets	523,152,240.91	491,189,419.80
Total Current Assets	<u>23,990,481,429.36</u>	<u>12,663,033,917.84</u>

Item	As at September 30, 2020	As at December 31, 2019
Non-current Assets:		
Long-term equity investments	826,617,657.55	793,506,346.91
Other non-current financial assets	5,812,706,851.88	4,009,081,069.57
Fixed assets	5,228,171,385.36	4,332,721,080.60
Construction in progress	2,535,775,765.31	2,091,667,072.04
Productive biological assets	375,235,000.00	360,253,830.00
Right-of-use assets	1,155,844,089.41	1,142,274,258.81
Intangible assets	1,008,963,498.21	918,038,106.73
Goodwill	1,455,873,623.54	1,362,176,212.72
Long-term deferred expenditures	1,265,318,554.59	1,253,832,614.95
Deferred tax assets	297,030,085.27	262,215,448.66
Other non-current assets	562,724,528.66	50,334,411.99
	<hr/>	<hr/>
Total Non-current Assets	20,524,261,039.78	16,576,100,452.98
	<hr/>	<hr/>
Total Assets	<u>44,514,742,469.14</u>	<u>29,239,134,370.82</u>
Current Liabilities:		
Short-term borrowings	1,513,666,500.00	1,604,257,325.12
Financial liabilities held for trading	24,140,035.03	19,498,803.04
Derivative financial liabilities	43,680,541.42	86,378,137.81
Note payables	11,818,925.60	19,089,888.52
Trade payables	823,931,431.52	573,097,931.92
Contract liabilities	1,281,163,042.04	897,139,905.65
Payroll payables	839,800,973.24	758,376,758.94
Tax payables	349,071,659.95	281,846,421.04
Other payables	2,277,095,941.72	2,045,666,329.43
Including: Interest payables	2,898,686.90	5,325,095.60
Dividend payables	3,700,000.00	—
Non-current liabilities due within one year	186,913,439.36	348,097,143.48
Other current liabilities	1,485,071.56	937,799.03
	<hr/>	<hr/>
Total Current Liabilities	7,352,767,561.44	6,634,386,443.98
	<hr/>	<hr/>

Item	As at September 30, 2020	As at December 31, 2019
Non-current Liabilities:		
Long-term borrowings	—	762,400,000.00
Bond payables	1,881,142,323.23	1,874,914,616.22
Including: Preference shares	—	—
Perpetual bonds	—	—
Rental liabilities	1,116,248,747.88	1,104,688,525.91
Deferred income	681,689,084.71	667,382,398.75
Deferred tax liabilities	239,158,325.63	231,097,542.54
Other non-current liabilities	1,159,074,595.42	554,554,757.31
Total Non-current Liabilities	<u>5,077,313,076.87</u>	<u>5,195,037,840.73</u>
Total Liabilities	<u>12,430,080,638.31</u>	<u>11,829,424,284.71</u>
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,442,020,829.00	1,651,126,531.00
Capital reserve	22,555,369,397.81	10,287,644,187.17
Less: Treasury shares	1,033,999,945.07	705,816,790.55
Other comprehensive income	197,893,833.37	156,245,363.37
Surplus reserve	146,215,359.82	146,215,359.82
Undistributed profit	<u>7,588,767,646.10</u>	<u>5,776,840,758.26</u>
Total Equity (or Shareholders' Equity) attributable to owners of the parent company	31,896,267,121.03	17,312,255,409.07
Minority interests	<u>188,394,709.80</u>	<u>97,454,677.04</u>
Total Owners' Equity (or Shareholders' Equity)	<u>32,084,661,830.83</u>	<u>17,409,710,086.11</u>
Total Liabilities and Owners' Equity (or Shareholders' Equity)	<u><u>44,514,742,469.14</u></u>	<u><u>29,239,134,370.82</u></u>
Legal Representative:	Ge Li	
Chief Financial Officer:	Ellis Bih-Hsin Chu	
Director of the Accounting Department:	Jin Sun	

Balance Sheet of the Parent Company

As at September 30, 2020

Prepared by: WuXi AppTec Co., Ltd.

Item	Unit: RMB	Type of audit: Unaudited
	As at September 30, 2020	As at December 31, 2019
Current Assets:		
Bank balance and cash	9,397,232,473.49	3,414,206,477.00
Financial assets held for trading	2,831,311,917.82	451,622,465.78
Prepayments	194,649.28	245,180.84
Other receivables	1,113,854,786.60	3,451,714,031.07
Including: Interest receivables	2,337,823.29	5,202,261.38
Dividend receivables	—	650,000,000.00
Other current assets	16,049,309.20	6,618,951.08
Total Current Assets	<u>13,358,643,136.39</u>	<u>7,324,407,105.77</u>
Non-current Assets:		
Long-term equity investments	15,068,303,312.06	8,884,910,358.54
Construction in progress	1,440,000.00	1,440,000.00
Intangible assets	89,136,843.76	90,884,625.00
Total Non-current Assets	<u>15,158,880,155.82</u>	<u>8,977,234,983.54</u>
Total Assets	<u><u>28,517,523,292.21</u></u>	<u><u>16,301,642,089.31</u></u>

Item	As at September 30, 2020	As at December 31, 2019
Current Liabilities:		
Payroll payables	158,620.36	15,147,379.40
Tax payables	—	10,686,822.43
Other payables	605,274,516.20	742,523,646.04
Including: Interest payables	—	—
Dividend payables	—	—
	<hr/>	<hr/>
Total Current Liabilities	<u>605,433,136.56</u>	<u>768,357,847.87</u>
Non-current Liabilities:		
Bond payables	1,881,142,323.23	1,874,914,616.22
Including: Preference Shares	—	—
Perpetual bonds	—	—
Other non-current liabilities	948,823,992.60	298,012,885.51
	<hr/>	<hr/>
Total Non-current Liabilities	<u>2,829,966,315.83</u>	<u>2,172,927,501.73</u>
Total Liabilities	<u>3,435,399,452.39</u>	<u>2,941,285,349.60</u>
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,442,020,829.00	1,651,126,531.00
Capital reserve	24,270,568,614.93	11,646,077,546.55
Less: Treasury shares	1,033,999,945.07	705,816,790.55
Surplus reserve	146,215,359.82	146,215,359.82
Undistributed profit	-742,681,018.86	622,754,092.89
	<hr/>	<hr/>
Total Owner's Equity (or Shareholders' equity)	<u>25,082,123,839.82</u>	<u>13,360,356,739.71</u>
Total Liabilities and Owners' Equity (or Shareholders' Equity)	<u><u>28,517,523,292.21</u></u>	<u><u>16,301,642,089.31</u></u>
Legal Representative:	Ge Li	
Chief Financial Officer:	Ellis Bih-Hsin Chu	
Director of the Accounting Department:	Jin Sun	

Consolidated Income Statement

January to September 2020

Prepared by: WuXi AppTec Co., Ltd

Item	Unit: RMB		Type of audit: Unaudited	
	Third quarter of 2020 (July — September)	Third quarter of 2019 (July — September)	First three quarters of 2020 (January — September)	First three quarters of 2019 (January — September)
I. Total revenue	4,583,368,978.34	3,384,155,804.66	11,814,802,985.22	9,278,514,251.38
Including: Revenue	4,583,368,978.34	3,384,155,804.66	11,814,802,985.22	9,278,514,251.38
II. Total cost	3,907,157,930.48	2,539,091,079.67	9,915,155,578.94	7,288,072,146.07
Including: Cost	2,811,769,972.90	2,004,453,094.76	7,374,781,534.27	5,612,735,942.99
Taxes and surcharges	7,663,334.20	4,420,243.64	23,489,740.63	19,866,202.71
Selling and marketing expenses	136,285,193.14	104,661,434.58	410,788,005.00	313,174,962.20
Administrative expenses	489,621,177.86	372,185,300.85	1,304,332,457.93	1,028,463,979.83
Research and development expenses	141,721,766.85	170,696,987.34	475,160,617.75	414,319,379.97
Finance expenses	320,096,485.53	-117,325,981.50	326,603,223.36	-100,488,321.63
Including: Interest expense	31,459,919.07	25,426,485.53	117,765,221.50	41,229,366.95
Interest income	16,531,660.05	12,719,911.75	42,212,862.68	64,563,264.19
Add: Other income	32,401,831.71	34,949,234.93	126,963,559.87	103,553,177.55
Investment gains (“-” indicating loss)	3,650,256.34	73,655,335.10	411,239,174.22	199,593,997.90
Including: Gains from investments in associates and joint ventures	-60,364,128.51	52,160,865.23	-90,684,351.77	104,937,141.53
Gains from changes in fair value (“-” indicating loss)	90,005,767.00	-77,783,461.98	312,090,742.03	-132,176,799.62
Credit impairment losses (“-” indicating loss)	-3,431,233.64	-8,886,650.83	-11,513,281.88	-10,038,827.73
Assets impairment losses (“-” indicating loss)	-4,365,528.25	-1,650,787.38	-10,173,426.54	-1,025,136.30
Gains on assets disposal (“-” indicating loss)	-2,055,148.61	-1,038,817.09	-4,566,306.12	1,035,391.87
III. Operating profit (“-” indicating loss)	792,416,992.41	864,309,577.74	2,723,687,867.86	2,151,383,908.98
Add: Non-operating income	879,776.46	368,516.31	3,087,147.88	1,342,760.21
Less: Non-operating expenses	7,158,686.47	177,719.61	18,675,386.55	6,759,572.67

Item	Third quarter of 2020 (July — September)	Third quarter of 2019 (July — September)	First three quarters of 2020 (January — September)	First three quarters of 2019 (January — September)
IV. Total profit (“-” indicating total loss)	786,138,082.40	864,500,374.44	2,708,099,629.19	2,145,967,096.52
Less: Income tax expenses	126,510,438.50	151,041,366.29	320,994,194.03	327,543,076.13
V. Net profit (“-” indicating net loss)	659,627,643.90	713,459,008.15	2,387,105,435.16	1,818,424,020.39
(I) Classified by continuity of operations				
1. Net profit from continuing operations (“-” indicating net loss)	659,627,643.90	713,459,008.15	2,387,105,435.16	1,818,424,020.39
2. Net profit from discontinued operations (“-” indicating net loss)	—	—	—	—
(II) Classified by ownership				
1. Net profit attributable to owners of the parent company (“-” indicating net loss)	651,201,091.63	708,384,430.87	2,368,356,528.79	1,765,146,773.87
2. Profit attributable to minority shareholders (“-” indicating net loss)	8,426,552.27	5,074,577.28	18,748,906.37	53,277,246.52
VI. Other comprehensive income, net of tax	-4,400,499.81	-8,336,848.05	43,504,321.35	47,275,770.54
(I) Other comprehensive income attributable to owners of the parent company, net of tax	-6,304,257.37	-7,919,136.41	41,648,470.00	44,029,150.62
1. Other comprehensive income that will not be reclassified to profit or loss	—	—	—	—
(1) Changes as a result of remeasurement of net defined benefit plan liability or asset	—	—	—	—
(2) Other comprehensive income that cannot be transferred to profit or loss accounted for using equity method	—	—	—	—
(3) Changes in fair value of other equity instrument investments	—	—	—	—
(4) Changes in fair value of enterprise’s own credit risk	—	—	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-6,304,257.37	-7,919,136.41	41,648,470.00	44,029,150.62
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—	—	—
(2) Changes in fair value of other debt investments	—	—	—	—
(3) Financial assets reclassified to other comprehensive income	—	—	—	—

Item	Third quarter of 2020 (July — September)	Third quarter of 2019 (July — September)	First three quarters of 2020 (January — September)	First three quarters of 2019 (January — September)
(4) Credit impairment allowance of other debt investments	—	—	—	—
(5) Cash flow hedging reserve	115,934,137.71	-98,587,786.55	123,109,973.33	-51,336,658.65
(6) Exchange difference on translation of foreign financial statements	-122,238,395.08	90,668,650.14	-81,461,503.33	95,365,809.27
(7) Others	—	—	—	—
(II) Other comprehensive income attributable to minority shareholders, net of tax	1,903,757.56	-417,711.64	1,855,851.35	3,246,619.92
VII. Total comprehensive income	655,227,144.09	705,122,160.10	2,430,609,756.51	1,865,699,790.93
(I) Total comprehensive income attributable to owners of the parent company	644,896,834.26	700,465,294.46	2,410,004,998.79	1,809,175,924.49
(II) Total comprehensive income attributable to minority shareholders	10,330,309.83	4,656,865.64	20,604,757.72	56,523,866.44
VIII. Earnings per share:				
(I) Basic earnings per share (RMB per share)	0.28	0.31	1.03	0.77
(II) Diluted earnings per share (RMB per share)	0.28	0.30	1.02	0.76

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was Nil (corresponding period of the previous year: Nil).

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

Income Statement of the Parent Company

January to September 2020

Prepared by: WuXi AppTec Co., Ltd.

Item	Unit: RMB		Type of audit: Unaudited	
	Third quarter of 2020 (July — September)	Third quarter of 2019 (July — September)	First three quarters of 2020 (January — September)	First three quarters of 2019 (January — September)
I. Revenue	—	—	—	—
Less: Cost	—	—	—	—
Taxes and surcharges	64,772.53	55,053.08	373,618.53	1,872,556.45
Administrative expenses	13,451,342.56	13,751,788.92	25,597,024.14	31,755,679.87
Finance expenses	161,712,708.58	-86,182,157.74	130,748,803.45	-123,460,118.39
Including: Interest expenses	17,500,481.90	6,694,900.03	52,136,714.71	6,694,900.03
Interest income	9,478,918.48	9,794,126.48	35,529,461.25	68,943,368.79
Add: Other income	232,283.54	69,593.35	6,525,716.09	1,076,713.64
Investment gains (“-” indicating loss)	6,249,058.60	5,407,293.75	21,400,515.59	13,840,730.57
Including: Gains from investments in associates and joint ventures	—	—	—	—
Gains from changes in fair value (“-” indicating loss)	-190,685,061.60	-40,132.21	-674,725,459.96	1,509,170.04
II. Operating profit (“-” indicating loss)	-359,432,543.13	77,812,070.63	-803,518,674.40	106,258,496.32
Add: Non-operating income	—	—	—	—
Less: Non-operating expenses	2,168,956.34	—	2,168,956.34	—
III. Total profit (“-” indicating total loss)	-361,601,499.47	77,812,070.63	-805,687,630.74	106,258,496.32
Less: Income tax expenses	-17,969,136.44	19,784,316.15	3,317,840.06	26,038,962.67

Item	Third quarter of 2020 (July — September)	Third quarter of 2019 (July — September)	First three quarters of 2020 (January — September)	First three quarters of 2019 (January — September)
IV. Net profit (“-” indicating net loss)	343,632,363.03	58,027,754.48	-809,005,470.80	80,219,533.65
(I) Net profit from continuing operations (“-” indicating net loss)	343,632,363.03	58,027,754.48	-809,005,470.80	80,219,533.65
(II) Net profit from discontinued operations (“-” indicating net loss)	—	—	—	—
V. Other comprehensive income (net of tax)	—	—	—	—
VI. Total comprehensive income	343,632,363.03	58,027,754.48	-809,005,470.80	80,219,533.65
VII. Earnings per share:				
(I) Basic earnings per share (RMB per share)	N/A	N/A	N/A	N/A
(II) Diluted earnings per share (RMB per share)	N/A	N/A	N/A	N/A

Legal Representative: Ge Li
Chief Financial Officer: Ellis Bih-Hsin Chu
Director of the Accounting Department: Jin Sun

Consolidated Statement of Cash Flows

January to September 2020

Prepared by: WuXi AppTec Co., Ltd.

Item	Unit: RMB	Type of audit: Unaudited
	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	11,734,779,320.85	8,682,845,176.38
Refunds of taxes and surcharges	383,550,855.93	265,376,801.69
Cash received relating to other operating activities	513,179,609.32	438,253,715.48
	<u>12,631,509,786.10</u>	<u>9,386,475,693.55</u>
Sub-total of cash inflow from operating activities		
Cash paid for purchasing goods and receiving services	5,084,323,959.27	3,559,056,647.35
Cash paid to and on behalf of employees	3,896,908,463.95	3,010,928,564.97
Payments of taxes and surcharges	485,276,529.31	371,629,062.58
Cash paid relating to other operating activities	743,095,965.44	671,676,400.05
	<u>10,209,604,917.97</u>	<u>7,613,290,674.95</u>
Sub-total of cash outflow from operating activities		
Net cash flow generated from operating activities	<u>2,421,904,868.13</u>	<u>1,773,185,018.60</u>

Item	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
II. Cash flow from investing activities:		
Cash received from disposal of investments	496,960,832.78	88,297,480.00
Cash received from return on investments	64,407,612.14	125,321,830.33
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	6,121,167.71	8,516,545.92
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
	<hr/>	<hr/>
Sub-total of cash inflow from investing activities	567,489,612.63	222,135,856.25
	<hr/>	<hr/>
Cash paid to acquire fixed assets, intangible assets and other long- term assets	1,920,021,281.00	1,831,514,200.42
Cash paid to acquire investments	3,171,932,989.21	2,160,319,258.63
Net cash paid to acquire subsidiaries and other business entities	41,945,756.27	130,248,530.45
Cash paid relating to other investing activities	—	—
	<hr/>	<hr/>
Sub-total of cash outflow from investing activities	5,133,900,026.48	4,122,081,989.50
	<hr/>	<hr/>
Net cash flow from investing activities	-4,566,410,413.85	-3,899,946,133.25

Item	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
III. Cash flow from financing activities:		
Cash received from capital contributions:	13,162,166,778.45	333,018,425.12
Including: Cash received from capital contribution by minority shareholders of subsidiaries	113,450,831.77	—
Cash received from borrowings	1,688,382,744.44	2,194,936,329.76
Cash received from bond issuance	—	2,083,882,461.21
Cash received relating to other financing activities	—	—
	<u>14,850,549,522.89</u>	<u>4,611,837,216.09</u>
Cash repayments of borrowings	2,720,608,396.56	120,000,000.00
Cash payments for distribution of dividends, profits or interest expenses	619,764,277.93	701,515,172.22
Including: Dividends and profits paid by subsidiaries to minority shareholders	—	—
Cash paid relating to other financing activities	1,266,122,839.90	2,787,154,159.90
	<u>4,606,495,514.39</u>	<u>3,608,669,332.12</u>
Sub-total of cash inflow from financing activities	<u>10,244,054,008.50</u>	<u>1,003,167,883.97</u>
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	<u>-23,181,616.30</u>	<u>4,298,579.44</u>
V. Net increase in cash and cash equivalents	8,076,366,846.48	-1,119,294,651.24
Add: Balance of cash and cash equivalents at the beginning of the period	<u>5,223,292,858.56</u>	<u>5,757,690,780.22</u>
VI. Balance of cash and cash equivalents at the end of the period	<u><u>13,299,659,705.04</u></u>	<u><u>4,638,396,128.98</u></u>

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

Cash Flow Statement of the Parent Company

January to September 2020

Prepared by: WuXi AppTec Co., Ltd.

Item	Unit: RMB	Type of audit: Unaudited
	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	—	—
Refunds of taxes and surcharges	—	—
Cash received relating to other operating activities	36,393,573.26	54,279,898.59
Sub-total of cash inflow from operating activities	36,393,573.26	54,279,898.59
Cash paid for purchasing goods and receiving services	—	—
Cash paid to and on behalf of employees	17,070,231.70	21,106,476.27
Payments of taxes and surcharges	23,877,995.65	1,872,556.45
Cash paid relating to other operating activities	12,171,301.77	7,716,246.34
Sub-total of cash outflow from operating activities	53,119,529.12	30,695,279.06
Net cash flow generated from operating activities	-16,725,955.86	23,584,619.53

Item	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
II. Cash flows from investment activities:		
Cash received from disposal of investments	—	—
Cash received from return on investments	671,400,515.59	513,840,730.57
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	—	—
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	11,016,616,569.39	1,645,696,823.74
Sub-total of cash inflow generated from investing activities	11,688,017,084.98	2,159,537,554.31
Cash paid to acquire fixed assets, intangible assets and other long- term assets	—	3,620,660.38
Cash paid to acquire investments	4,437,089,675.98	2,666,366,984.01
Net cash paid to acquire subsidiaries and other business entities	—	—
Cash paid relating to other investing activities	<u>13,258,396,521.31</u>	<u>2,235,678,959.92</u>
Sub-total of cash outflow from investing activities	<u>17,695,486,197.29</u>	<u>4,905,666,604.31</u>
Net cash flow generated from investing activities	<u>-6,007,469,112.31</u>	<u>-2,746,129,050.00</u>

Item	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
III. Cash flow from financing activities:		
Cash received from investments	13,048,715,946.68	323,767,915.19
Cash received from borrowings	—	—
Cash received from bond issuance	—	2,083,882,461.21
Cash received relating to other financing activities	—	—
	<hr/>	<hr/>
Sub-total of cash inflow from financing activities	13,048,715,946.68	2,407,650,376.40
	<hr/>	<hr/>
Cash repayments of borrowings	—	—
Cash payments for distribution of dividends, profits or interest expenses	556,429,640.95	678,641,317.31
Cash paid relating to other financing activities	637,723,853.59	52,341,464.42
	<hr/>	<hr/>
Sub-total of cash outflow from financing activities	1,194,153,494.54	730,982,781.73
	<hr/>	<hr/>
Net cash flow generated from financing activities	11,854,562,452.14	1,676,667,594.67
	<hr/>	<hr/>
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	-16,278,467.44	-11,955,650.36
	<hr/>	<hr/>
V. Net increase in cash and cash equivalents	5,814,088,916.53	-1,057,832,486.16
Add: Balance of cash and cash equivalents at the beginning of the period	3,414,206,477.00	4,472,837,985.45
	<hr/>	<hr/>
VI. Balance of cash and cash equivalents at the end of the period	<u>9,228,295,393.53</u>	<u>3,415,005,499.29</u>

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

4.2 Adjustments on the financial statements at the beginning of the first year of adopting new revenue standards and new leasing standards since 2020

Applicable ✓ Not applicable

4.3 Explanation of first adoption of new financial instrument standards and comparative data of retrospective adjustment of the previous reporting period of new leasing standards.

Applicable ✓ Not applicable

4.4 Auditor's Report

Applicable ✓ Not applicable

4.5 Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

Consolidated Statement of Profit or Loss and Other Comprehensive Income January to September 2020

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000		Type of audit: Unaudited	
	Third quarter of 2020 (July – September)	Third quarter of 2019 (July – September)	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
Revenue	4,583,369	3,384,156	11,814,803	9,278,514
Cost of services	<u>(2,818,740)</u>	<u>(2,007,272)</u>	<u>(7,391,589)</u>	<u>(5,618,039)</u>
Gross profit	1,764,629	1,376,884	4,423,214	3,660,475
Other income	62,642	53,899	190,614	178,772
Other gains and losses	(156,347)	76,871	565,456	54,378
Impairment losses under expected credit losses ("ECL") model, net of reversal	(3,431)	(8,887)	(11,513)	(10,039)
Selling and marketing expenses	(136,285)	(104,661)	(410,788)	(313,175)
Administrative expenses	(495,804)	(376,706)	(1,325,061)	(1,047,946)
Research and development expenses	<u>(141,722)</u>	<u>(170,697)</u>	<u>(475,161)</u>	<u>(414,319)</u>
Operating profit	893,682	846,703	2,956,761	2,108,146
Share of (losses) profits of associates	(58,080)	62,200	(75,993)	135,178
Share of losses of joint ventures	(2,284)	(10,039)	(14,692)	(30,241)
Finance costs	<u>(47,180)</u>	<u>(34,363)</u>	<u>(157,977)</u>	<u>(67,116)</u>
Profit before tax	786,138	864,500	2,708,099	2,145,967
Income tax expense	<u>(126,510)</u>	<u>(151,041)</u>	<u>(320,994)</u>	<u>(327,543)</u>
Profit for the period	<u><u>659,628</u></u>	<u><u>713,459</u></u>	<u><u>2,387,105</u></u>	<u><u>1,818,424</u></u>

	Third quarter of 2020 (July – September)	Third quarter of 2019 (July – September)	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
Other comprehensive income (expense) for the period				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of financial statements of foreign operations	(121,070)	90,277	(80,530)	96,324
Fair value gain (losses) on — hedging instrument designated in cash flow hedges	116,670	(99,308)	124,034	(49,048)
Other comprehensive income for the period, net of income tax	(4,400)	(9,031)	43,504	47,276
Total comprehensive income for the period	<u>655,228</u>	<u>704,428</u>	<u>2,430,609</u>	<u>1,865,700</u>
Profit for the period attributable to:				
Owners of the Company	651,201	708,384	2,368,357	1,765,147
Non-controlling interests	8,427	5,075	18,748	53,277
	<u>659,628</u>	<u>713,459</u>	<u>2,387,105</u>	<u>1,818,424</u>
Total comprehensive income for the period attributable to:				
Owners of the Company	644,897	700,465	2,410,005	1,809,176
Non-controlling interests	10,331	3,963	20,604	56,524
	<u>655,228</u>	<u>704,428</u>	<u>2,430,609</u>	<u>1,865,700</u>
Earnings per share (expressed in RMB per share)				
— Basic	<u>0.28</u>	<u>0.31</u>	<u>1.03</u>	<u>0.77</u>
— Diluted	<u>0.28</u>	<u>0.30</u>	<u>1.02</u>	<u>0.76</u>

Consolidated Statement of Financial Position

As at September 30, 2020

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000	Type of audit: Unaudited
	As at	As at
	September 30,	December 31,
	2020	2019
Non-current Assets		
Property, plant and equipment	9,007,498	7,665,990
Right of use assets	1,570,948	1,564,438
Goodwill	1,455,874	1,362,176
Other intangible assets	593,860	495,874
Interest in associates	777,658	768,292
Interest in joint ventures	48,959	25,215
Deferred tax assets	297,030	262,215
Financial assets at fair value through profit or loss (“FVTPL”)	5,812,707	4,009,081
Other non-current assets	584,318	62,391
Biological assets	375,235	360,254
Amount due from related parties	174	174
	20,524,261	16,576,100
Total Non-current Assets		
Current Assets		
Inventories	1,794,315	1,208,320
Contract costs	187,839	180,201
Biological assets	379,926	353,964
Amounts due from related parties	10,443	13,342
Trade and other receivables	4,342,202	3,555,889
Contract assets	509,976	379,396
Income tax recoverable	7,332	6,286
Financial assets at FVTPL	3,022,027	1,701,638
Derivative financial instruments	261,068	36,755
Pledged bank deposits	175,694	3,950
Bank balances and cash	13,299,660	5,223,293
	23,990,482	12,663,034
Total Current Assets		
	44,514,743	29,239,134
Total Assets		

	As at September 30, 2020	As at December 31, 2019
Current Liabilities		
Trade and other payables	3,981,908	3,392,829
Amounts due to related parties	19,418	24,796
Derivative financial instruments	43,681	86,378
Contract liabilities	1,281,163	897,140
Borrowings	1,528,667	1,809,857
Lease liabilities	171,913	142,497
Financial liabilities at FVTPL	24,140	19,499
Income tax payables	301,878	261,390
	<hr/>	<hr/>
Total Current Liabilities	7,352,768	6,634,386
Non-current Liabilities		
Borrowings	—	762,400
Deferred tax liabilities	239,158	231,098
Deferred income	681,689	667,382
Convertible bonds-debt component	1,881,142	1,874,915
Convertible bonds-embedded derivative component	948,824	298,013
Lease liabilities	1,116,249	1,104,689
Financial liabilities at FVTPL	—	24,729
Other long-term liabilities	210,251	231,812
	<hr/>	<hr/>
Total Non-current Liabilities	5,077,313	5,195,038
	<hr/>	<hr/>
Total Liabilities	12,430,081	11,829,424
Equity		
Share capital	2,442,021	1,651,127
Reserves	29,454,246	15,661,128
	<hr/>	<hr/>
Equity attributable to owners of the Company	31,896,267	17,312,255
Non-controlling interests	188,395	97,455
	<hr/>	<hr/>
Total Equity	32,084,662	17,409,710
	<hr/> <hr/>	<hr/> <hr/>

Consolidated Statement of Cash Flows

January to September 2020

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000	Type of audit: Unaudited
	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
Net cash from operating activities	2,354,841	1,572,801
Net cash used in investing activities		
Interests received	35,390	61,850
Proceeds from disposal of financial assets at FVTPL	496,961	88,297
Purchase of financial assets at FVTPL	(2,517,416)	(1,989,525)
Proceeds from disposal of property, plant and equipment	6,086	7,858
Proceeds from disposal of other intangible assets	35	659
Purchase of other non-current assets	(500,000)	—
Acquisition of interests in associates	(100,816)	(126,220)
Acquisition of interests in joint ventures	(26,667)	(20,865)
Purchase of property, plant and equipment	(1,883,532)	(1,650,478)
Purchase of right-of-use assets	—	(71,287)
Refund (Payment) for lease deposits	3,655	(33,741)
Purchase of other intangible assets	(36,489)	(32,260)
Purchase of biological assets	—	(77,489)
Placement of pledged bank deposits	(2,807)	(1,303)
Net cash outflow on acquisition of subsidiaries	(41,946)	(130,249)
Dividends received from associates	2,075	11,487
Dividends received from financial assets at FVTPL	62,333	113,835
Government grants and subsidies received related to assets	30,825	173,574
Payment for forward contracts	(27,033)	(23,708)
	(4,499,346)	(3,699,565)

	First three quarters of 2020 (January – September)	First three quarters of 2019 (January – September)
Net cash from financing activities		
Payment of dividends	(556,430)	(678,641)
New borrowings raised	1,688,383	2,194,936
Repayment of borrowings	(2,720,608)	(120,000)
Acquisition of partial interest of a subsidiary from non-controlling shareholders	(462,176)	(2,421,243)
Proceeds from issue of H shares under the over- allotment option	—	308,235
Proceeds from issue of H shares under the Placing Agreement	6,564,329	—
Proceeds from non-public issue of A shares	6,465,924	—
Contribution from non-controlling shareholders	113,451	—
Proceeds from issue of Restricted A shares and exercise of share options	18,462	24,784
Interests paid	(63,334)	(22,874)
Repurchase and cancellation of restrict A shares	(20,535)	(12,305)
Repayment of lease liabilities	(166,223)	(113,313)
Repayments of consideration payable on purchase of a property under instalment payment plan	—	(200,255)
Issue cost paid	(2,085)	(40,036)
Proceeds form issue of Convertible Bonds	—	2,083,882
Repurchase of H shares for share incentive scheme	(615,104)	—
	<u>10,244,054</u>	<u>1,003,170</u>
Net increase (decrease) in cash and cash equivalents	8,099,549	(1,123,594)
Cash and cash equivalents at the beginning of period	5,223,293	5,757,691
Effects of exchange rate changes	(23,182)	4,299
	<u>13,299,660</u>	<u>4,638,396</u>
Cash and cash equivalents at the end of period	<u>13,299,660</u>	<u>4,638,396</u>